Disc’s rebuffed rare blood disease drug sets up FDA re-do after ‘clean’ Phase 3 sweep
Start here
Disc Medicine announced that bitopertin met all primary endpoints in the Phase 3 APOLLO trial in EPP (N=183): PPIX fell 41.4% versus placebo (p<0.0001), and sunlight tolerance at month six increased by 12.2 hours (p=0.0010). All secondary endpoints were also positive.
Excerpted from BioSpace
Coverage timeline
Follow the coverage to see the different angles.
- BioSpacePickDisc’s rebuffed rare blood disease drug sets up FDA re-do after ‘clean’ Phase 3 sweep
Disc Medicine announced that bitopertin met all primary endpoints in the Phase 3 APOLLO trial in EPP (N=183): PPIX fell 41.4% versus placebo (p<0.0001), and sunlight tolerance at month six increased by 12.2 hours (p=0.0010). All secondary endpoints were also positive.
Coverage and heat for this story
Reports so far 1·Heat now 9·Peak heat 10 (Oct 19 20:00)·Reports, 24h +1
Two panels, same clock (pointer stays in sync): top is cumulative editorial reports — only rises; last point = All reports; slope = new reports that hour. Bottom is Live-board heatIndex — 7-day participants with a 24-hour half-life, so it can fall when talk cools.